CSBio CSBio

X
[{"orgOrder":0,"company":"Biophytis","sponsor":"BPI","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Receives \u20ac980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Biophytis"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies.

            Lead Product(s): BIO201

            Therapeutic Area: Ophthalmology Product Name: Macuneos

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: BPI

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Funding April 29, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY